Cover Image

Cost-effectiveness of bortezomib for multiple myeloma: a systematic review

Wendong Chen,1 Yicheng Yang,2 Yi Chen,3 Fen Du,3 Huan Zhan3 1Normin Health, Toronto, ON, Canada; 2Xian Janssen, Beijing, People's Republic of China; 3Normin Health Changsha Representative Office, Changsha, People's Republic of China Objectives: To review published cost-effectiveness...

Full description

Saved in:

Bibliographic Details
Main Authors:	Chen W (Author), Yang Y (Author), Chen Y (Author), Du F (Author), Zhan H (Author)
Format:	Book
Published:	Dove Medical Press, 2016-05-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Subcutaneous bortezomib might be standard of care for patients with multiple myeloma: a systematic review and meta-analysis
by: Ye Z, et al.
Published: (2019)

Cost-Effectiveness Analysis of Adding Daratumumab to Bortezomib, Melphalan, and Prednisone for Untreated Multiple Myeloma
by: Yaohua Cao, et al.
Published: (2021)

ID221 Bortezomib for the treatment of Multiple Myeloma: A Systematic Review and Meta-Analysis
by: Vania dos Santos Nunes Nogueira, et al.
Published: (2024)

Bortezomib-Induced Reticular Eruption in Patient with Multiple Myeloma
by: Joseph Han, et al.
Published: (2023)

Clinical Assessment of Bortezomib for Multiple Myeloma in Comparison with Thalidomide
by: Mitsutoshi Satoh, et al.
Published: (2011)

Review on Bortezomib Resistance in Multiple Myeloma and Potential Role of Emerging Technologies
by: Gül Kozalak, et al.
Published: (2023)

Skin lesions caused by bortezomib targeted therapy of multiple myeloma
by: Michał Sobjanek, et al.
Published: (2016)

Optimized Liposomal Delivery of Bortezomib for Advancing Treatment of Multiple Myeloma
by: Chi Zhang, et al.
Published: (2023)

Cytokine and Chemokine Profile in Patients with Multiple Myeloma Treated with Bortezomib
by: Paweł Robak, et al.
Published: (2020)

Bortezomib therapy in a real-world setting in patients with relapsed or refractory multiple myeloma
by: Shang-Yi Huang, et al.
Published: (2019)

SHP2 Inhibitors Show Anti-Myeloma Activity and Synergize With Bortezomib in the Treatment of Multiple Myeloma
by: Pan Zhou, et al.
Published: (2022)

Disease biology alters the response to frontline bortezomib, lenalidomide and dexamethasone in Multiple Myeloma
by: Amany R Keruakous, et al.
Published: (2021)

US Budget Impact Model for Selinexor, Bortezomib, and Dexamethasone for the Treatment of Previously Treated Multiple Myeloma
by: Dolph M, et al.
Published: (2021)

Pharmacodynamic Models of Differential Bortezomib Signaling Across Several Cell Lines of Multiple Myeloma
by: Vidya Ramakrishnan, et al.
Published: (2019)

Role of combination bortezomib and pegylated liposomal doxorubicin in the management of relapsed and/or refractory multiple myeloma
by: Jatin J Shah, et al.
Published: (2009)

Synthesis of a Bone-Targeted Bortezomib with In Vivo Anti-Myeloma Effects in Mice
by: Hua Wang, et al.
Published: (2018)

Celastrol Attenuates the Invasion and Migration and Augments the Anticancer Effects of Bortezomib in a Xenograft Mouse Model of Multiple Myeloma
by: Muthu K. Shanmugam, et al.
Published: (2018)

Reduced weekly subcutaneous doses of bortezomib in combination with cyclophosphamide and dexamethasone for newly diagnosed multiple myeloma
by: Farzaneh Ashrafi, et al.
Published: (2020)

Cutaneous Drug Reaction Due to Bortezomib Characterized by Erythematous Reticular Plaques in a Patient With Multiple Myeloma
by: Emre Güven, et al.
Published: (2024)

Bortezomib-Based Regimens for Newly Diagnosed Multiple Myeloma in China: A Report of 12-Year Real-World Data
by: Jingsong He, et al.
Published: (2020)

KS18, a Mcl-1 inhibitor, improves the effectiveness of bortezomib and overcomes resistance in refractory multiple myeloma by triggering intrinsic apoptosis
by: Omar S. Al-Odat, et al.
Published: (2024)

Bortezomib modulates CHIT1 and YKL40 in monocyte-derived osteoclast and in myeloma cells
by: Tibullo eDaniele, et al.
Published: (2015)

Circular RNA circPSAP functions as an efficient miR-331-3p sponge to regulate proliferation, apoptosis and bortezomib sensitivity of human multiple myeloma cells by upregulating HDAC4
by: Hongyan Ma, et al.
Published: (2022)

Complete remission of scleredema adultorum of Buschke associated with multiple myeloma after bortezomib-based treatment and autologous peripheral blood stem cell transplantation
by: Hsing-Jou Su, et al.
Published: (2021)

Application of the cost-effectiveness method in improving the pharmacotherapy of multiple myeloma
by: E. A. Luchinin, et al.
Published: (2023)

Inflammatory and Nutritional Scoring System for Predicting Prognosis in Patients with Newly Diagnosed Multiple Myeloma
by: Zhang L, et al.
Published: (2023)

Cost-effectiveness analysis of treating transplant-eligible multiple myeloma patients in Macedonia
by: Qerimi V, et al.
Published: (2018)

Multiple Myeloma
Published: (2021)

Multiple Myeloma An Overview
Published: (2012)

T‐cell pseudolymphoma secondary to ixazomib for multiple myeloma
by: M. Haq, et al.
Published: (2021)

Synergistic effect of venetoclax and teglicar in multiple myeloma cell lines
by: Belal A. Al-Husein, et al.
Published: (2024)

TLR4 Signaling and Heme Oxygenase-1/Carbon Monoxide Pathway Crosstalk Induces Resiliency of Myeloma Plasma Cells to Bortezomib Treatment
by: Grazia Scandura, et al.
Published: (2022)

Update on Multiple Myeloma
Published: (2019)

Immunotherapy in Multiple Myeloma
Published: (2019)

Integrins in multiple myeloma
by: Naoki Hosen
Published: (2020)

Therapeutic use of anti-sclerostin antibody in the treatment of multiple myeloma: A systematic review
by: Liza Ngomdir, et al.
Published: (2023)

Multiple myeloma and cardiovascular risk (a literature review)
by: B. B. Samura, et al.
Published: (2020)

Multiple Myeloma A Quick Reflection on the Fast Progress
Published: (2013)

Investigation of the Underlying Mechanism of Sclerosteosis Expression in Muscle Tissue in Multiple Myeloma with Sarcopenia
by: Ren J, et al.
Published: (2023)

Development and characterization of liposomal formulation of bortezomib
by: Anil K. Deshantri, et al.
Published: (2019)